The erbB family of receptor tyrosine kinases is frequently implicated in neoplasia. Ampli®cation and overexpression of erbB2/neu has been found in 20 to 40% of human breast cancers. Previous studies using MMTV/c-neu transgenic mice have linked rat neu overexpression to mammary tumor development. In this study, we provide evidence that rat neu overexpression in mammary tumors of MMTV/c-neu transgenic mice is always associated with demethylation of the MMTV promoter, whereas the normal mammary glands of these transgenic mice always contain speci®c methylated regions of the MMTV promoter. In addition, after exposure to N-methyl-N-nitrosourea (MNU), the latency of mammary tumor development is signi®cantly reduced and again is also associated with MMTV promoter demethylation. Thus, the transition from methylation to hypomethylation of the MMTV promoter induces highlevel expression of c-neu and appears to be a prerequisite for transformation from normal to malignant mammary epithelium, either spontaneously or after carcinogen exposure. Expression of transgenic c-neu from the demethylated MMTV promoter appears to be an early event that allows outgrowth of mammary epithelium predisposed to malignant transformation. Oncogene (2001) 20, 6009 ± 6017.
Introduction
The ErbB family members of tyrosine kinase growth factor receptors are highly expressed in a broad spectrum of tumor types (Cohen et al., 1998; Hung and Lau, 1999) . Formation of homodimers and/or heterodimers between the four known receptors, erbB1 (EGFR), erbB2 (neu), erbB3 and erbB4, activate the receptors' intrinsic tyrosine kinase activity, inducing phosphorylation and activation of the Ras-Raf-MAPkinase signaling pathway (Alroy and Yarden, 1997) . Among these receptors, erbB2/neu ampli®cation and overexpression in human breast and ovarian tumors correlate with earlier patient relapse and poor prognosis (Andrulis et al., 1998; Slamon et al., 1987 Slamon et al., , 1989 Menard et al., 2000) . To directly assess the association between erbB2/neu overexpression and mammary carcinogenesis, several rat neu transgenic mice lines have been established under the transcriptional control of the mouse mammary tumor virus [MMTV] promoter (Bouchard et al., 1989; Guy et al., 1992; Muller et al., 1988; Siegel et al., 1994 Siegel et al., , 1999 Singal and Ginder, 1999) . In these models, overexpression of either the activated or unactivated neu oncogene results in the development of mammary tumors.
It has been shown that MNU can induce mammary tumors in rats (Lu and Archer, 1992) , often associated with H-ras mutational activation (Zarbl et al., 1985) . In order to evaluate the role of methylation in mammary carcinogenesis in the mouse and to study possible synergy with c-neu overexpression, study the sensitivity of the unactivated rat c-neu transgenic mice to MNU, we treated the female MMTV-c-neu mice at 6 weeks of age with a single dose of 50 mg/kg body weight MNU (Dumenco et al., 1993) . We found that MNU treatment signi®cantly shortens the latency of mammary tumor development in these mice. Furthermore, we found rat cneu to be highly expressed in both MNU-induced and spontaneous mammary tumors but not in the normal mammary epithelium. To our surprise, overexpression was associated with MMTV promoter hypomethylation whereas the promoter was consistently methylated and transgenic c-neu was not expressed in the normal glands. This suggests that promoter demethylation might be an early carcinogenic event.
Hypomethylation of a number of genes may occur early in carcinogenesis (Cervoni et al., 1999; Rao et al., 1989) . However, little is known about the molecular and biochemical mechanisms involved. Treatment of cells with the methylating agents, N-methyl-N-nitrosourea (MNU), has been shown to provoke hypomethylation Drahovsky, 1981, 1983a,b -alkylguanine DNAalkyltransferase (AGT), mismatch repair (MMR) and base excision repair (BER). Of the various DNA adducts, the most mutagenic and carcinogenic is O 6 -mG. If these adducts remain unrepaired, the DNA damage becomes an initiating event that may lead to point mutations or chromosomal rearrangments that activate proto-oncogenes and/or silence tumor suppressor genes. The carcinogenic properties of MNU have been extensively studied in animals (Dumenco et al., 1993; Fong et al., 1990; Frei and Lawley, 1980) . Previous studies in this lab have shown that MNU induces thymic lymphomas in both DNA repair de®cient mice and wildtype mice. Moreover, the induction of these tumors could be inhibited by over-expression of MGMT (Allay et al., 1997; Dumenco et al., 1993; Qin et al., 1999a,b) , which speci®cally catalyzes the transfer of a methyl group from O 6 -methylguanine (O 6 -mG) to its own cysteine residue (Gerson et al., 1985) . Surprisingly, although MNU induces mammary gland tumors in rats it does so only infrequently in mice. The availability of the MMTV c-neu mouse let us address whether these mice would become susceptible to MNU induced mammary carcinogenesis.
Results

Mammary carcinoma induction by MNU
We investigated whether the methylating carcinogen, MNU, would impact mammary tumor development in unactivated c-neu transgenic mice. No MNU treated mice developed mammary tumors in either the FVB or FVB/B6SJL background wild-type mice observed for up to 1 year. In contrast, homozygous c-neu (+/+) transgenic mice with MNU treatment had an induced incidence of mammary tumors of 57.9%, and for single allele c-neu (+/7) transgenic mice with MNU exposure, the incidence of mammary tumors was 33.3% (Table 1a ,b). Compared with the spontaneous incidence of mammary tumors in c-neu transgenic mice, the total incidence of mammary tumors was not increased after MNU exposure but this may have been impacted by early death resulting from MNU-induced thymic lymphomas (see below). However, MNU shortened the latency of mammary tumor development (Figure 1 ) to 143 vs 205 days in c-neu (+/+) mice (Table 1a) , P50.05; and 232 vs 445 days in c-neu (+/7) mice, (Table 1b) , P50.05. Most of the mammary tumors in these mice were adenocarcinomas without distant metastasis, as con®rmed by histopathology ( Figure 2a ). We did not see signi®cant hyperplasia or dysplasia around the tumor tissue, nor in adjacent mammary glands.
The c-neu transgene is highly expressed in mammary tumors and is accompanied by overexpression of endogenous erbB3
To determine the expression level of erbB family proteins in mammary tumors, we performed Western blotting. The expression of EGFR, erbB2/neu, erbB3 and erbB4 was compared in both tumor and adjacent normal mammary tissue from dierent glands of paired animals. As depicted in Figure 3a ,b, both transgenic neu and endogenous erbB3 were highly expressed in the tumors but not in normal mammary tissue *FVB/B6SJL background mice; # tumors other than lymphoma; m, lung adenocarcinoma, n, 2 lung adenocarcinoma; 1 myosarcoma of uterus; 1 liver tumor with lung adenocarcinoma; 1 ovary tumor harvested from the same mice. Neither EGFR nor erbB4 was highly expressed in normal or tumor tissue (data not shown). RT ± PCR was performed in both mammary tumors and paired normal mammary tissues, con®rming that the transgenic rat neu, as opposed to endogenous neu, was expressed in the tumor tissue, with minimal or no expression of the transgene seen in the normal glands ( Figure 3c ). Immunostaining of erbB2/neu also showed clear expression of rat c-neu on the membrane of mammary tumor cells, but not on the adjacent or paired normal mammary epithelial cells ( Figure 2b ). During extensive evaluation of normal glands, no evidence of c-neu expression was obtained.
The MMTV-LTR is demethylated in mammary tumors but not in normal mammary tissue
Since we had expected to ®nd MMTV-erbB2 overexpression in mammary tumors, we were surprised to ®nd the absence of expression in normal mammary tissue and postulated that promoter methylation might be a factor. We performed bisul®de treatment followed by PCR and sequencing analysis of the CpG rich regions of the MMTV-LTR (see Figure 4a ,b). We found that all mammary tumors (12 tumors from 12 dierent mice) exhibited MMTV promoter hypomethylation in almost all CpG sites within region 1. Both PCR-subclone-sequencing and direct-PCR sequencing showed all CpG sites were completely hypomethylated in region 1 (except one site in one tumor sample). In contrast, all normal mammary samples (a total of eight sets of mammary glands from eight dierent mice) showed evidence of transgene MMTV promoter methylation in region 1. None of the normal glands had evidence of complete demethylation of the MMTV promoter, suggesting that complete promoter demethylation within the transgene concatimer was required for gene expression to occur. Of note, there was no dierence in the degree of methylation in region 2 of the MMTV promoter of normal glands and mammary tumors. In this region, CpG sites are not as frequent and its status does not appear to in¯uence gene expression. 
MNU did not change the promoter methylation status within 6 weeks
Because spontaneous demethylation of the MMTV promoter in mammary tumors was observed beyond 3 months of age, and MNU induced tumors earlier than that, we wondered whether we could detect MMTV promoter hypomethylation immediately after MNU. Mice were treated with MNU and the MMTV promoter methylation assay was performed on the vivisected mammary glands 5 days prior and 1, 3, 6 weeks after MNU injection. No signi®cant methylation changes of CpG promoter regions 1 or 2 were found (Figure 4b ). At this time point, no tumors or hyperplasia were noted in the glands. In addition, in contrast to the mammary tumors, neu immunostaining was not observed in normal mammary glands ( Figure  2b ).
Mutation screen of K-ras and neu
Since H-ras mutations are common after MNU treatment in rat mammary tumors, and since K-ras appears to be the target in the mouse, 20 tumor samples were checked for K-ras mutations by the PCR-RFLP method previously described (Zaidi et al., 1995) . No G to A point mutations in codon 12 of K-ras was found. Fifteen tumor samples were checked by RT ± PCR followed by DNA sequencing of the extracellular and transmembrane domains of c-neu. Only one of these samples showed an 18 bp inframe deletion of cneu, which was from a spontaneous tumor. Two out of seven tumor samples from MNU treated mice had point mutations of c-neu within this region, one with G to A and A to G transitions, and the other with a T to A transversion.
Thymic lymphoma development
Neither c-neu transgenic mice nor wild-type mice developed spontaneous thymic lymphomas. MNU treated mice developed thymic lymphomas at the cumulative incidence of 40% in wild-type FVB and 44% in FVB/B6SJL background mice after a 50 mg/kg dose of MNU was given at 6 weeks of age. A similar incidence (44.7% and 38.9%) of MNU-induced lymphomas with a mean latency of 180 days was observed in c-neu +/+ and c-neu +/7 transgenic mice respectively (Table 1a ,b). There was no evidence of c-neu expression by Western blot in the thymic lymphomas of c-neu mice (data not shown), and the CpG sites were not demethylated in these thymus tissues.
Discussion
The key ®ndings of this study are that MMTV promoter methylation appears to prevent c-neu expression in the mammary glands of transgenic mice until either a carcinogenic switch, or outgrowth takes place that results in the appearance of tumors expressing high levels of c-neu as well as endogenous erbB-3. In the process, the tumors have evidence of MMTV promoter demethylation. In addition, MNU, which is not a common mammary carcinogen in the mouse, potentiates the carcinogenicity of c-neu by signi®cantly shortening latency. However, the overall incidence of mammary tumor development in the c-neu transgenic mice was not increased. This might have been biased by the death of many mice from thymic lymphomas which occurs in about 50% of mice between 110 and 160 days after In contrast 5'-methylcytosine remains unchanged. In this example, the cytosines within the CpG island of region 1 (vertical arrows) from a normal mammary gland were methylated whereas they were completely unmethylated in a paired mammary tumor sample MNU. On the other hand, c-neu did not appear to in¯uence the onset or incidence of thymic lymphomas and these lymphomas did not express transgenic c-neu or endogenous erbB3, as was observed in the mammary tumors (data not shown).
K-ras mutations are commonly observed in mouse tumors, especially after methylating agent exposure. Recently, it has been observed that transgenic rats carrying human c-Ha-ras are highly susceptible to MNU mammary carcinogenesis (Asamoto et al., 2000) . Thus, we asked whether K-ras mutations might contribute to the decreased mammary tumor latency observed after MNU exposure. We postulated that the erbB proteins utilize the Ras-Raf-MAP-kinase as a major proliferative signaling pathway, and that activated K-ras would potentiate this pathway. However, no K-ras mutations were found in 20 mammary tumors. We also screened for mutations or deletions within the transmembrane domain of transgenic c-neu, which has previously been shown to result in c-neu activation during carcinogenesis (Bouchard et al., 1989; Muller et al., 1988; Siegel et al., 1999; Singal and Ginder, 1999) . One out of nine spontaneous tumor samples tested had an 18 bp in-frame deletion and two out of seven MNU induced tumors had dierent single point mutations, but none of these are in the region expected to be associated with c-neu activation. This indicates that activating mutations of K-ras and c-neu do not contribute to c-neu-associated mammary tumors in these mice.
C-neu heterodimerization is a common requirement of tumorigenesis, giving rise to potent Ras-Raf-MAPkinase pathway activation. We identi®ed endogenous erbB3 expression in the mammary tumors, indicating that it serves as the partner whereas endogenous EGFR or erbB4 (data not shown) were not expressed in any of the mammary tumors studied in this series. In addition, neither c-neu or erbB-3 proteins were expressed in adjacent normal tissues. Thus, c-neu expression appears a requisite for tumor induction.
Since there was such a striking match between transgenic erbB2, endogenous erbB3 expression, and tumorigenesis in the spontaneous tumors and those induced, with shorter latency, by MNU, we examined the methylation status of the transgene MMTV promotor regions and found striking dierences between tumor and normal glands. Promoter region methylation is a powerful mechanism for the suppression of gene activity. Viral promoters become progressively methylated upon integration into mammalian genomes Lorincz et al., 2000; Orend et al., 1995) . It has been proposed that de novo methylation constitutes a cellular defense mechanism to silence integrated foreign DNA or genes (Doer¯er et al., 1997; Garrick et al., 1998; Pikaart et al., 1998) . Transgene silencing by methylation was observed in globin/lacZ transgenic mice with increasing age (Robertson et al., 1996) . It has also been shown that transgenes under control of the methylated MMTV ± LTR were not expressed in mammary glands in most founder mice and their descendants (Betzl et al., 1996) .
The reciprocal relationship between the density of methylated cytosine residues in the promoter regions and the transcriptional activity of a gene has been widely documented.
We examined two MMTV promoter regions with CpG islands (Figure 4a ), region 1 which contains condensed CpG sites, and region 2 which has more dispersed CpG sites. These regions covered one authentic AP2 consensus sequence (within region 1) and other relatively homologous AP1, AP4, CTF-NFI and E4TF1 transcription factor binding sites ( Figure  4a) . It has been shown that DNA demethylation will reduce interference for transcription factor binding, subsequently activating transcription (Singal and Ginder, 1999) . AP2 is an important transcription factor that is sensitive to the methylation status of its cognate binding site. In this collection of mammary tumors, CpG island methylation in region 1 correlated inversely with gene expression whereas CpG island methylation in region 2 did not.
In the MMTV c-neu transgenic mice used in these experiments, basal neu expression was very low, no glandular hyperplasia was seen and the MMTV promoter region is not hypomethylated. Others have reported that the MMTV neu mouse mammary gland develops hyperplasia and that neu is expressed in those glands (Guy et al., 1992 ). It appears that in the process of breeding MMTV neu mice through multiple generations the MMTV promoter may have become methylated, turning o c-neu expression and leading to the latency phenotype (no c-neu expression) observed in these studies. Progressive intergenerational transgene promoter methylation has been described in other settings (Challita and Kohn, 1994; Robertson et al., 1996) and may have occurred here.
The mechanism and time of onset of DNA demethylation in these mice is obscure, as it often is. Apart from the overall genomic hypomethylation in cancer cells, speci®c oncogenes have been observed to be hypomethylated in human tumors. An inverse correlation between demethylation and gene expression was observed in the antiapoptotic bcl-2 gene in B-cell chronic lymphocytic leukemia (Hanada et al., 1993) and for the K-ras proto-oncogene in lung and colon carcinomas (Feinberg and Vogelstein, 1983) . In other settings, a number of tumor suppressor genes, including p16 and MGMT, have been noted to be hypermethylated in cancer cells (Baylin and Herman, 2000; Baylin et al., 1998; Issa, 2000) . Nonetheless, the regulatory mechanisms controlling the methylation status at speci®c sites have not been elucidated. In addition, it is still not known whether demethylation is a contributing factor to, or a result of carcinogenic events.
Furthermore, the demethylation process seems to have been accelerated by MNU, resulting in tumors with shorter latency. One possible explanation is that MNU, which forms O 6 -methylguanine, N 7 -methylguanine and N 3 -methyladenine DNA adducts, may aect the 5' methylcytosine methyltransferase, perhaps directly inhibiting methyl group transfer to cytosine. A second interpretation may be that DNA methylation adduct repair by O 6 -alkylguanine DNA-alkyltransferase, mis-match repair or base excision repair may interfere with the 5' cytocine methyltransferase or otherwise alter chromatin methylation. In support of this hypothesis, it was recognized many years ago that treatment of cells with MNU provokes DNA demethylation (Boehm and Drahovsky, 1983a) , and results in both upregulation and suppression of gene expression (Young et al., 1996) .
This study suggests that demethylation of a transgenic oncogene promoter, whether spontaneous or MNU-induced, may be carcinogenic. Whether this mechanism is also at play for endogenous tumorpromoting genes remains to be determined.
Materials and methods
Chemicals
Taq DNA polymerase, Trizol Reagent, proteinase K and agarose were purchased from Gibco BRL (Gaithersburg), MNU was from Sigma (St. Louis, MO, USA).
Antibodies
Primary antibodies against c-erbB2/HER-2 were purchased from Upstate Biotechnology Incorporated (UBI; Lake Saranac, NY, USA), ErbB1/EGFR and ErbB3/HER-3 from NeoMarker (Union City, CA, USA), ErbB4 was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and actin from Sigma. HRP-conjugated anti-rabbit antibody was from Amersham (Piscataway, NJ, USA). Rabbit anti-mouse IgG was from from Upstate Biotechnology Incorporated (UBI; Lake Saranac, NY, USA).
c-neu transgenic mice
The unactivated c-neu (rat) transgenic mice were generated by Muller and colleagues. (Guy et al., 1992) . Ospring were crossed to generate a founder line of c-neu +/+ transgenic mice in the FVB background. The mice were mated with wild-type B6SJL mice, generating the F1 heterozygous c-neu (+/7) mice for these experiments. The genotype of all mice was determined by PCR ampli®cation of tail DNA. Five hundred mg tail DNA was digested in 500 ml proteinase k solution: 50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 100 mM NaCl, 1% Triton X-100 and 1 mg/ml proteinase K at 558C overnight. PCR was performed under the following conditions: 10 mM This-HCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 50 mM dNTPs, 500 nM in each primer, 5 ml 10 times diluted tail DNA, 0.5 U TaqDNA polymerase for total 25 ml. The rat neu primer sequences have been previously published (Siegel et al., 1994) , and have yielded a product of 625 bp, which partially covered both the extracellular domain and transmembrane domain. Thirty cycles of PCR were utilized: 948C for 45 s, 588C for 45 s, 708C for 45 s. Mice were observed for development of tumor nodules.
Animal treatment
Eighteen +/7 c-neu transgenic mice, 38 +/+ c-neu transgenic mice, and 35 non-transgenic mice were given a single i.p. injection of MNU at a dose of 50 mg/kg body weight at 6 weeks of age. Sixteen c-neu +/7, 20 c-neu +/+ transgenic mice and 29 non-transgenic mice were observed for spontaneous mammary tumor development. The mice were palpitated twice a week and the date of the ®rst tumor was recorded as the time of onset. When mice demonstrated a protruding mammary, they were sacri®ced under carbon dioxide (CO 2 ) anesthesia and autopsied. Tumor tissue and adjacent normal mammary tissue were dissected and 50 mg of tissue were freshly prepared for RNA and RT ± PCR. The remaining tumor and organ sections were further divided and frozen in liquid nitrogen and stored at 7808C or ®xed in 10% buered formalin and embedded in paran. Mammary tumor-free survival curves were plotted by Kaplan-Meier Cumulative Survival Curves and compared by standard statistical techniques using Statview software with the Chisquare test. Mean tumor latencies were compared by t-test.
Animal surgery
Female MMTV c-neu transgenic mice were anesthetized by i.p. injection with a mixture of Rompun (xylazine, 1.7*3.43 ug/g of body weight), Ketaset (ketamine HCl,) and Acepromazine (0.5*1 mg/g of body weight), which were purchased from Henry Schein (135 Duryea Road, Melville, NY 11747, USA). One mammary gland was vivisected 5 days before MNU treatment. The mice were then treated with MNU as previously described. Individual mammary glands were then vivisected 1, 3 and 6 weeks after MNU injection. Mammary tissue DNA was prepared for further methylation analysis.
Histology and immunohistochemistry
Three-micron sections were placed on regular slides and stained with Hematoxylin and Eosin. Four-micron sections were applied to lycine coated slides. After being deparanized and rehydrated, antigen unmasking was performed by heat treatment with 10 mM sodium citrate buer (pH 6.0) at 958C for 5 min. Slides were allowed to cool in the buer for 20 min, washed with deionized H 2 O and incubated 5 min in 0.5% hydrogen peroxide to quench endogenous peroxidase activity. After blocking for 30 min in 0.5% goat serum in 16PBS, the sections were incubated overnight at 48C with a primary goat polyclonal antibody against neu (Santa Cruz Biotechnology, Inc.) at a dilution of 1 : 100. Primary antibody binding was localized by using an avidin-biotin-peroxidase kit, ImmunoCruz Staining Systems (Santa Cruz Biotechnology, Inc.).
Western blotting
Tumor and normal mammary tissues were sonicated in icecold RIPA buer plus protease inhibitors and a tyrosine phosphatase inhibitor (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM PMSF, 1 mg/ml pepstatin A, 0.2 U/ml aprotinin, 0.5 mg/ml leupeptin, 1 mM Na 3 VO 4 ) and cleared by centrifugation in a Beckman tabletop. The protein concentrations of lysates were determined with the Bio-Rad (Hercules, CA, USA) Dc detergent-compatible assay, using bovine serum albumin (BSA; Boehringer-Mannheim) as a standard.
For Western blots, 50 mg of total tissue proteins were loaded per well. Rainbow TM coloured protein molecular weight markers (Amersham Life Science, Little Chalfont, Buckinghamshire, UK) were also loaded. Proteins were then transferred to PVDF membranes (Biotechnology Systems, Boston, MA, USA). After blocking in 5% non-fat dry milk TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at RT, blots were incubated with primary antibody overnight at 48C, washed three times with TBST, incubated with HRP-conjugated secondary antibody for 1 h, washed three times with TBST, then developed by ECL (Amersham) and exposed to X-Omat ®lm (Kodak, NEN Life Science).
PCR ± RFLP mutation screen of K-ras Mammary tumors from 20 mice were checked for activating G to A transition mutations in codon 12 of K-ras using a two-step PCR ± RFLP method, as previously described (Qin et al., 1999a; Zaidi et al., 1995) .
RT ± PCR
Total RNA was extracted from 25 mg of both tumor and normal mammary tissues with Trizol Reagent (Gibco BRL) and treated with DNase I (Boehringer Mannheim, Indianapolis, IN, USA). Reverse transcription was performed under the following conditions: 0.5 mg oligo (dT) 12 ± 18 , 2 mg RNA, 20 mM Tris-HCl, 50 mM KCl, 2.5 mM MgCl 2 , 0.5 mM dNTP mix , 10 mM DTT, 200 U SuperScript II RT, with a total amount of 20 ml for 2 h at 428C. Reactions were diluted to 200 ml with H 2 O and 10 ml aliquots were used in PCR reactions using the same rat c-neu primers and following the same conditions described above. As a control, manufacturer supplied (Ambion) primers for mouse 18S RNA were used. The RT ± PCR products for rat c-neu transmembrane domain were subcloned and sequenced.
Assay for MMTV ± LTR methylation
Genomic DNA was isolated from 50 mg of various mouse tissues using DNAzol. Normal and tumor mammary samples from dierent mice were analysed. Five hundred ng DNA from each sample in a volume of 50 ml was denatured in NaOH (freshly made, ®nal concentration, 0.2 M) at 378C for 15 min. Next, 30 ml 10 mM hydroquinone (fresh) and 520 ml 3.0 M NaHSO 4 (freshly prepared sodium bisul®te, pH 5.0) were added, and incubated at 558C for 16 h. Modi®ed DNA was puri®ed using Wizard DNA Clean up kit (Promega). The reaction was desulphonated by NaOH at a ®nal concentration of 0.3 M at room temperature for 15 min and neutralized by adding NH 4 OAc, pH 7.0, to a ®nal concentration of 3 M. DNA was precipitated with three volumes of ethanol for 30 min at 7808C. The DNA pellet was then dissolved in distilled water to give approximately 10 ng/ml. Bisul®te treated DNA was used as the template for subsequent PCR and sequencing. The primer sequences were based on the MMTV LTR sequence and were speci®c for fully modi®ed DNA. Primers for the sense strand were MMTVF1: 5-GAGAAGTAGTTAAGGGGTTGTTTT-TTAT-3 and MMTVF2: 5-GGTGTAAGGATTAAGGGTT-TTGGT-3 and primers for the antisense strand were MMTVR1:
5-AAATTAACTATAATCCTTACCCCAAA-AA-3 and MMTVR2: 5-TCTTCCTAAATTAACACACAC-CAAAAAA-3, which amplify the region corresponding to nucleotides 56 to 316 and 531 to 805 of the MMTV LTR sequence. PCR was carried out using a hot start and the following cycling parameters: 40 cycles of 958C (45 s), 588C (45 s), 728C (45 s); 728C (10 min), and 48C to cool. We used two sequencing methods: direct sequencing of PCR products, or sequencing PCR products subcloned into a pCR2.1-Topo vector.
